Patent intelligence · US
US 12226455
Medical composition for treating cardiac wasting and cachexia
Medical composition for treating cardiac wasting and cachexia
Patent details — US 12226455
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 18, 2025
- Expiration
- Feb 13, 2045
- Applicant
- RELAXERA PHARMAZEUTISCHE GMBH & CO. KG
- Claims
- 6
- CPC classes
- A61K, A61K38/2221, A61P, A61P9/02
Quick answer
US 12226455 (Medical composition for treating cardiac wasting and cachexia) is held by RELAXERA PHARMAZEUTISCHE GMBH & CO. KG. Status: granted. Granted Feb 18, 2025. Expires Feb 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- RELAXERA PHARMAZEUTISCHE GMBH & CO. KG
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K38/2221, A61P, A61P9/02, A61P9/04
More from RELAXERA PHARMAZEUTISCHE GMBH & CO. KG
Related pharmaceutical patents in our USPTO index.
-
US 12310943
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12297182
Compositions comprising an urolithin compound
granted -
US 12220424
Compositions comprising nicotinamide riboside and a urolithin
granted -
US 12109190
Urolithins as immune response enhancers
granted -
US 12036205
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12030863
Prodrugs of urolithins and uses thereof
granted -
US 11969408
Method for improving mitophagy in subjects
granted
Frequently asked questions
What is US patent 12226455?
US 12226455 (Medical composition for treating cardiac wasting and cachexia) is held by RELAXERA PHARMAZEUTISCHE GMBH & CO. KG. Status: granted. Granted Feb 18, 2025. Expires Feb 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12226455?
RELAXERA PHARMAZEUTISCHE GMBH & CO. KG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.
When does US 12226455 expire?
Our index shows an expiration date of Feb 13, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.